Gastrointestinal illnesses are a major cause of disease worldwide. The growth in incidence of Inflammatory Bowel Diseases (IBD) along with the continued effort to eradicate the causative agent of stomach cancer has led to the need for novel and non-invasive diagnostic testing. DiaSorin Stool Diagnostic products offer reliable diagnostic results.
The DiaSorin LIAISON®Calprotectin assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the quantitative measurement, in human stool, of fecal calprotectin, a neutrophilic protein that is a marker of mucosal inflammation. The LIAISON® Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS). Test results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures.
In the United States the CDC now estimates over 3 million people being diagnosed with IBD. As a result, increased hospitalization costs to address IBD are placing a large financial burden on healthcare. The DiaSorin LIAISON® Calprotectin assay provides a non-invasive method to detect and monitor the on-going treatment of IBD.
The DiaSorin LIAISON® Elastase-1 assay is a chemiluminescent immunoassay (CLIA) intended for the quantitative determination of fecal pancreatic elastase in human stool specimens from adults and children. The test is an aid for the diagnosis of exocrine pancreatic insufficiency.
Highly stable through the gastrointestinal tract, elastase-1 can be measured in a reliable non-invasive method to detect pancreatic insufficiency. Pancreatic insufficiency can often be found in patients with chronic pancreatitis, some cases of pancreatic cancer, cystic fibrosis, Shwachman-Diamond syndrome, and celiac disease as well as other diseases that affect the pancreas.
The LIAISON® Meridian H. pylori SA assay is a chemiluminescent immunoassay (CUA) intended for the qualitative determination of Helicobacter pylori (H. pylori) antigen in human stool. The test is an aid in the diagnosis of patients suspected of H. pylori infection and to measure post therapy response from patients who have discontinued therapy for at least 4 weeks.
Studies show that H.pylori bacteria is the primary cause of ulcers, (9 out of 10) and in extreme cases leads to gastric cancer. The LIAISON® Meridian H. pylori SA assay is a fast, accurate and efficient test to support therapeutic decisions-making.
